Healthcare / Pharmaceutical RetailersTokyo
$1129.00
-11.00 (-0.96%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $500.5M · quality 54.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
49/100
C
Piotroski
8/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.2B
P/E
15.7x
↓EV/EBITDA
4.1x
↓ROE
7.9%
↑Gross Margin
10.0%
↓Debt/Equity
0.89
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+6.9%
FCF CAGR
—
FCF margin
2.1%
FCF / Net income
1.67x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $23.83B · net income $299.9M · FCF $500.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $23.83B | $23.83B | $22.72B | $22.25B | $19.51B |
| Net Income | $299.9M | $299.9M | $5.5M | $209.6M | $291.6M |
| EBITDA | $1.15B | $1.15B | $748.7M | $1.03B | $1.09B |
| EPS | 113.05 | 113.05 | 2.20 | 83.84 | 116.61 |
| Gross Margin | 10.0% | 10.0% | 9.5% | 9.0% | 9.7% |
| Operating Margin | 2.7% | 2.7% | 1.7% | 0.9% | 1.0% |
| Net Margin | 1.3% | 1.3% | 0.0% | 0.9% | 1.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.89 | 0.89 | 1.33 | 1.49 | 1.64 |
| Current Ratio | 0.80 | 0.80 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $500.5M | $500.5M | $1.29B | $482.0M | $-3.2M |
| Returns | |||||
| ROE | 7.9% | 7.9% | 0.2% | 6.3% | 9.1% |
| Valuation | |||||
| P/E | 15.74 | 15.74 | 478.18 | 11.89 | 8.60 |
| EV/EBITDA | 4.11 | 4.11 | 6.89 | 6.05 | 6.11 |
| P/B | 0.79 | 0.79 | 0.80 | 0.75 | 0.78 |
| Growth & Yield | |||||
| Revenue Growth | 4.9% | 4.9% | 2.1% | 14.0% | — |
| EPS Growth | 5038.6% | 5038.6% | -97.4% | -28.1% | — |
| Dividend Yield | 2.6% | 2.6% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-3.9%
EPS terminal req.
$100.18
Spread vs growth
5042.6%
5Y implied EPS CAGR
1.4%
EPS terminal req.
$121.22
Spread vs growth
5037.2%
10Y implied EPS CAGR
5.6%
EPS terminal req.
$195.22
Spread vs growth
5033.0%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+7.1%
Start / end P/E
491.4x → 10.0x
EPS bridge
2.20 → 113.05
Residual
-4936.2%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.